PNC Financial Services Group
CRVS icon

PNC Financial Services Group’s Corvus Pharmaceuticals CRVS Stock Holding History

PNC Financial Services Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39K Buy
160
+23
+17% +$319 ﹤0.01% 4614
2026
Q1 		$2K Hold
137
– – ﹤0.01% 4579
2025
Q4 		$1.05K Sell
137
-162
-54% -$1.28K ﹤0.01% 4680
2025
Q3 		$2.2K Buy
+299
New +$1.53K ﹤0.01% 4474
2022
Q1 		– Sell
-3,000
Closed -$7K – 4551
2021
Q4 		$7K Buy
+3,000
New +$11.6K ﹤0.01% 3869

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PNC Financial Services Group's CRVS Position: Q2 2026 in Review

PNC Financial Services Group increased its Corvus Pharmaceuticals (CRVS) stake by 17% in Q2 2026, buying an estimated $319 and bringing the position to 160 shares worth $2.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4614.

PNC Financial Services Group first reported a position in CRVS in Q4 2021 and has held it in 5 quarters since. The position peaked at $7K in Q4 2021. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • PNC Financial Services Group held 160 shares of Corvus Pharmaceuticals worth $2.39K as of Q2 2026.
  • PNC Financial Services Group bought 23 Corvus Pharmaceuticals shares in Q2 2026, an estimated $319.
  • Corvus Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4614 holding.
  • PNC Financial Services Group first reported a position in Corvus Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • PNC Financial Services Group's Corvus Pharmaceuticals position peaked at $7K in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.